MaltSci 麦伴科研

Appearance

文献精选 > 近年高分"mRNA疫苗"研究（IF≥30，近5年）

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. ​

文献信息 ​

DOI10.1016/j.ccell.2021.06.009
PMID34214473
期刊Cancer cell
影响因子44.5
JCR 分区Q1
发表年份2021
被引次数156
关键词COVID-19, 抗癌治疗, 抗体, 免疫反应, 恶性肿瘤
文献类型Journal Article
ISSN1535-6108
页码1091-1098.e2
期号39(8)
作者Alfredo Addeo, Pankil K Shah, Natacha Bordry, Robert D Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre-Yves Dietrich, Barbara S Taylor, Pierre-Francois Simand, Darpan Patel, Jing Wang, Intidhar Labidi-Galy, Sara Fertani, Robin J Leach, Jose Sandoval, Ruben Mesa, Kate Lathrop, Nicolas Mach, Dimpy P Shah

一句话小结 ​

本研究评估了SARS-CoV-2 mRNA疫苗在癌症患者中的有效性，发现94%的患者在接种后实现了血清转化，但血液恶性肿瘤患者的血清转化率和抗体滴度显著低于实体瘤患者，且接受抗CD-20抗体治疗的患者未产生抗体反应。这一发现强调了针对癌症患者的疫苗接种策略的重要性，提示需关注不同癌症类型对疫苗反应的影响。

在麦伴科研 (maltsci.com) 搜索更多文献 ​

COVID-19 · 抗癌治疗 · 抗体 · 免疫反应 · 恶性肿瘤

摘要 ​

癌症患者在SARS-CoV-2感染、疾病严重程度、并发症和死亡率方面的负担高于普通人群。虽然SARS-CoV-2 mRNA疫苗在普通人群中具有很高的有效性，但关于其在癌症患者中的有效性的数据却相对较少。我们通过前瞻性队列研究，评估了2021年1月至4月期间，接受BNT162b2和mRNA-1273 SARS-CoV-2疫苗的癌症患者的血清转化率和抗SARS-CoV-2刺突蛋白抗体滴度。在131名患者中，大多数（94%）在接种两剂疫苗后实现了血清转化。血液恶性肿瘤患者的血清转化率和抗体滴度显著低于实体瘤患者。在接种疫苗前6个月有接受抗CD-20抗体治疗史的患者均未产生抗体反应。临床监测或内分泌治疗组的抗体滴度最高，而接受细胞毒性化疗或单克隆抗体治疗组的抗体滴度最低。

英文摘要 ​

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

麦伴智能科研服务 ​

智能阅读回答你对文献的任何问题，帮助理解文献中的复杂图表和公式
定位观点定位某个观点在文献中的蛛丝马迹
加入知识库完成数据提取，报告撰写等更多高级知识挖掘功能

主要研究问题 ​

  1. 患者在接受不同类型癌症治疗时，mRNA疫苗的免疫应答是否存在显著差异？
  2. 在接种mRNA疫苗后，患者的抗体反应持续时间如何，是否会影响后续疫苗接种策略？
  3. 针对不同癌症类型的患者，mRNA疫苗的免疫原性如何评估，是否需要个性化的接种方案？
  4. 在肿瘤患者中，哪些因素（如年龄、合并症等）可能影响mRNA疫苗的免疫反应？
  5. 目前关于癌症患者接种mRNA疫苗的长期安全性和有效性的研究进展如何？

核心洞察 ​

研究背景和目的 ​

COVID-19大流行对癌症患者的影响显著，他们面临更高的感染风险和病死率。尽管mRNA疫苗在普通人群中表现出良好的有效性，但关于其在癌症患者中的免疫反应数据相对缺乏。本研究旨在评估癌症患者在接种mRNA COVID-19疫苗后抗体的产生情况，以了解疫苗在该特定人群中的免疫原性。

主要方法/材料/实验设计 ​

本研究为前瞻性队列研究，涉及在美国和欧洲的两家癌症中心的癌症患者。参与者接受BNT162b2或mRNA-1273疫苗，数据收集时间为2021年1月至4月。主要研究指标为接种第一剂和第二剂疫苗后的抗SARS-CoV-2刺突蛋白抗体（IgG）阳性转化率和抗体滴度。

实验设计流程图 ​

Mermaid diagram

关键结果和发现 ​

  • 患者特征：共招募140名癌症患者，其中131名为SARS-CoV-2阴性患者。
  • 抗体阳性转化率：接种第二剂后94%的患者实现了抗体阳性转化；第一剂后仅有81%。
  • 肿瘤类型影响：血液恶性肿瘤患者的抗体阳性转化率（77%）显著低于实体肿瘤患者（98%）。
  • 治疗影响：接受抗-CD20抗体治疗的患者在接种两剂疫苗后未能产生抗体。
  • 抗体滴度：接受内分泌治疗的患者抗体滴度最高，而接受细胞毒性化疗的患者抗体滴度最低。

主要结论/意义/创新性 ​

本研究表明，癌症患者在接种两剂mRNA疫苗后大多数能够产生抗体，但血液恶性肿瘤患者和接受免疫抑制治疗的患者的免疫反应明显不足。这一发现强调了对免疫抑制患者的疫苗接种策略进行个性化调整的必要性，可能需要考虑额外的疫苗剂量或其他保护措施。

研究局限性和未来方向 ​

  • 局限性：缺乏对细胞免疫反应的评估；样本中某些少数族裔患者数量较少，可能影响结果的普遍性。
  • 未来方向：建议进行更大规模的多中心研究，以进一步验证这些发现，并探索在免疫抑制患者中优化疫苗接种的策略。

参考文献 ​

  1. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. - Livia Mazzini;Donata Martinuzzi;Inesa Hyseni;Linda Benincasa;Eleonora Molesti;Elisa Casa;Giulia Lapini;Pietro Piu;Claudia Maria Trombetta;Serena Marchi;Ilaria Razzano;Alessandro Manenti;Emanuele Montomoli - Journal of immunological methods (2021)
  2. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. - P Grivas;A R Khaki;T M Wise-Draper;B French;C Hennessy;C-Y Hsu;Y Shyr;X Li;T K Choueiri;C A Painter;S Peters;B I Rini;M A Thompson;S Mishra;D R Rivera;J D Acoba;M Z Abidi;Z Bakouny;B Bashir;T Bekaii-Saab;S Berg;E H Bernicker;M A Bilen;P Bindal;R Bishnoi;N Bouganim;D W Bowles;A Cabal;P F Caimi;D D Chism;J Crowell;C Curran;A Desai;B Dixon;D B Doroshow;E B Durbin;A Elkrief;D Farmakiotis;A Fazio;L A Fecher;D B Flora;C R Friese;J Fu;S M Gadgeel;M D Galsky;D M Gill;M J Glover;S Goyal;P Grover;S Gulati;S Gupta;S Halabi;T R Halfdanarson;B Halmos;D J Hausrath;J E Hawley;E Hsu;M Huynh-Le;C Hwang;C Jani;A Jayaraj;D B Johnson;A Kasi;H Khan;V S Koshkin;N M Kuderer;D H Kwon;P E Lammers;A Li;A Loaiza-Bonilla;C A Low;M B Lustberg;G H Lyman;R R McKay;C McNair;H Menon;R A Mesa;V Mico;D Mundt;G Nagaraj;E S Nakasone;J Nakayama;A Nizam;N L Nock;C Park;J M Patel;K G Patel;P Peddi;N A Pennell;A J Piper-Vallillo;M Puc;D Ravindranathan;M E Reeves;D Y Reuben;L Rosenstein;R P Rosovsky;S M Rubinstein;M Salazar;A L Schmidt;G K Schwartz;M R Shah;S A Shah;C Shah;J A Shaya;S R K Singh;M Smits;K E Stockerl-Goldstein;D G Stover;M Streckfuss;S Subbiah;L Tachiki;E Tadesse;A Thakkar;M D Tucker;A K Verma;D C Vinh;M Weiss;J T Wu;E Wulff-Burchfield;Z Xie;P P Yu;T Zhang;A Y Zhou;H Zhu;L Zubiri;D P Shah;J L Warner;GdL Lopes - Annals of oncology : official journal of the European Society for Medical Oncology (2021)
  3. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. - Nicole M Kuderer;Toni K Choueiri;Dimpy P Shah;Yu Shyr;Samuel M Rubinstein;Donna R Rivera;Sanjay Shete;Chih-Yuan Hsu;Aakash Desai;Gilberto de Lima Lopes;Petros Grivas;Corrie A Painter;Solange Peters;Michael A Thompson;Ziad Bakouny;Gerald Batist;Tanios Bekaii-Saab;Mehmet A Bilen;Nathaniel Bouganim;Mateo Bover Larroya;Daniel Castellano;Salvatore A Del Prete;Deborah B Doroshow;Pamela C Egan;Arielle Elkrief;Dimitrios Farmakiotis;Daniel Flora;Matthew D Galsky;Michael J Glover;Elizabeth A Griffiths;Anthony P Gulati;Shilpa Gupta;Navid Hafez;Thorvardur R Halfdanarson;Jessica E Hawley;Emily Hsu;Anup Kasi;Ali R Khaki;Christopher A Lemmon;Colleen Lewis;Barbara Logan;Tyler Masters;Rana R McKay;Ruben A Mesa;Alicia K Morgans;Mary F Mulcahy;Orestis A Panagiotou;Prakash Peddi;Nathan A Pennell;Kerry Reynolds;Lane R Rosen;Rachel Rosovsky;Mary Salazar;Andrew Schmidt;Sumit A Shah;Justin A Shaya;John Steinharter;Keith E Stockerl-Goldstein;Suki Subbiah;Donald C Vinh;Firas H Wehbe;Lisa B Weissmann;Julie Tsu-Yu Wu;Elizabeth Wulff-Burchfield;Zhuoer Xie;Albert Yeh;Peter P Yu;Alice Y Zhou;Leyre Zubiri;Sanjay Mishra;Gary H Lyman;Brian I Rini;Jeremy L Warner; - Lancet (London, England) (2020)
  4. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. - Evangelos Terpos;Ioannis P Trougakos;Maria Gavriatopoulou;Ioannis Papassotiriou;Aimilia D Sklirou;Ioannis Ntanasis-Stathopoulos;Eleni-Dimitra Papanagnou;Despina Fotiou;Efstathios Kastritis;Meletios A Dimopoulos - Blood (2021)
  5. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. - Amir Massarweh;Noa Eliakim-Raz;Amos Stemmer;Adva Levy-Barda;Shlomit Yust-Katz;Alona Zer;Alexandra Benouaich-Amiel;Haim Ben-Zvi;Neta Moskovits;Baruch Brenner;Jihad Bishara;Dafna Yahav;Boaz Tadmor;Tal Zaks;Salomon M Stemmer - JAMA oncology (2021)
  6. COVID-19 and Cancer: Current Challenges and Perspectives. - Ziad Bakouny;Jessica E Hawley;Toni K Choueiri;Solange Peters;Brian I Rini;Jeremy L Warner;Corrie A Painter - Cancer cell (2020)
  7. Care without a compass: Including patients with cancer in COVID-19 studies. - Christopher R Friese;Toni K Choueiri;Narjust Duma;Dimitrios Farmakiotis;Petros Grivas;Brian I Rini;Dimpy P Shah;Michael A Thompson;Steven A Pergam;Sanjay Mishra;Jeremy L Warner - Cancer cell (2021)
  8. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. - Leticia Monin;Adam G Laing;Miguel Muñoz-Ruiz;Duncan R McKenzie;Irene Del Molino Del Barrio;Thanussuyah Alaguthurai;Clara Domingo-Vila;Thomas S Hayday;Carl Graham;Jeffrey Seow;Sultan Abdul-Jawad;Shraddha Kamdar;Elizabeth Harvey-Jones;Rosalind Graham;Jack Cooper;Muhammad Khan;Jennifer Vidler;Helen Kakkassery;Shubhankar Sinha;Richard Davis;Liane Dupont;Isaac Francos Quijorna;Charlotte O'Brien-Gore;Puay Ling Lee;Josephine Eum;Maria Conde Poole;Magdalene Joseph;Daniel Davies;Yin Wu;Angela Swampillai;Bernard V North;Ana Montes;Mark Harries;Anne Rigg;James Spicer;Michael H Malim;Paul Fields;Piers Patten;Francesca Di Rosa;Sophie Papa;Timothy Tree;Katie J Doores;Adrian C Hayday;Sheeba Irshad - The Lancet. Oncology (2021)
  9. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. - QuanQiu Wang;Nathan A Berger;Rong Xu - JAMA oncology (2021)
  10. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. - R Palich;M Veyri;S Marot;A Vozy;J Gligorov;P Maingon;A-G Marcelin;J-P Spano - Annals of oncology : official journal of the European Society for Medical Oncology (2021)

引用本文的文献 ​

  1. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. - Joshua A Hill;Chaitra S Ujjani;Alexander L Greninger;Mazyar Shadman;Ajay K Gopal - Cancer cell (2021)
  2. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. - Oliver Van Oekelen;Charles R Gleason;Sarita Agte;Komal Srivastava;Katherine F Beach;Adolfo Aleman;Katerina Kappes; ;Tarek H Mouhieddine;Bo Wang;Ajai Chari;Carlos Cordon-Cardo;Florian Krammer;Sundar Jagannath;Viviana Simon;Ania Wajnberg;Samir Parekh - Cancer cell (2021)
  3. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. - Elizabeth A Griffiths;Brahm H Segal - Cancer cell (2021)
  4. A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein. - Rémi Vernet;Emily Charrier;Julien Grogg;Nicolas Mach - Vaccines (2021)
  5. COVID-19 Vaccine Among Actively-Treated People With Cancer: A Glimpse Into the Known Unknowns? - Astha Thakkar;Sanjay Mishra;Jeremy L Warner - Journal of the National Cancer Institute (2022)
  6. Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. - Josef Singer;Nguyen-Son Le;Daniel Mattes;Valerie Klamminger;Klaus Hackner;Nicole Kolinsky;Michaela Scherb;Peter Errhalt;Gudrun Kreye;Martin Pecherstorfer;Sonia Vallet;Klaus Podar - Cancers (2021)
  7. SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients? - Niklas Zojer - Memo (2021)
  8. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. - Helena Linardou;Nikolaos Spanakis;Georgia-Angeliki Koliou;Athina Christopoulou;Sofia Karageorgopoulou;Nephely Alevra;Anastasios Vagionas;Nikolaos Tsoukalas;Stavroula Sgourou;Elena Fountzilas;Joseph Sgouros;Evangelia Razis;Dimitra Chatzokou;Sofia Lampaki;Eleni Res;Zacharenia Saridaki;Giannis Mountzios;George Saroglou;George Fountzilas - Cancers (2021)
  9. Influence of Health Beliefs on COVID-19 Vaccination among Individuals with Cancer and Other Comorbidities in Puerto Rico. - McClaren Rodriguez;Andrea López-Cepero;Ana P Ortiz-Martínez;Emma Fernández-Repollet;Cynthia M Pérez - Vaccines (2021)
  10. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. - A Grinshpun;Y Rottenberg;I Z Ben-Dov;E Djian;D G Wolf;L Kadouri - ESMO open (2021)

... (146 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研